Healthcare Providers Acquire Financial Aid amid Ongoing COVID-19 Outbreak
Out-of-hospital care is anticipated to surge during the COVID-19 period. Stakeholders in the brucellosis vaccine market are increasing the availability of home healthcare providers, rehabilitation facilities, and long term care facilities. In-patient and community-based providers should review the current capacity for patients in both settings and plan for future pandemic-like situations.
Companies in the brucellosis vaccine market are scrambling to maintain robust supply chains to improve patient outcomes and meet demands. They are looking for financial aid by governments and organizing employee wellness programs to prevent & mitigate burnout, review pay & benefits compared with the industry average. Interrupted clinical research and clinical trial activities are now being conducted utilizing telehealth options wherever possible.
Educational & Training Programs Help Control Brucellosis Disease in Colombia
Due to the presence of brucellosis in several susceptible production livestock systems scattered throughout Colombia, companies in the brucellosis vaccine market are making plans for its control, prevention, and eradication over the years. However, despite extensive efforts, brucellosis prevalence has fluctuated over the years without any trend of decreasing. Hence, companies are creating awareness about high impact educational and training programs required to address the disease in a comprehensive manner.
Companies in the Colombia brucellosis vaccine market are targeting vulnerable groups such as traditional smallholders, veterinary authorities, and communities in low productivity regions for their educational and training programs.
India Holds Lucrative Incremental Opportunities for Brucellosis Vaccine Manufacturers
The global brucellosis vaccine market is projected to grow at a CAGR of 4% during the forecast period. Companies are tapping value-grab opportunities in India, since the Animal Husbandry Department in Yadgir has planned to vaccinate cattle and buffalo calves to prevent brucellosis disease under the National Animal Disease Control Programme (NADCP). Several thousand cattle and buffalo calves are being vaccinated under this flagship scheme launched by the Union Government of India.
Since brucellosis is a serious infectious disease that can cause abortion or loss of reproductivity, companies in the India brucellosis vaccine market are increasing output capacities to improve clinical outcomes in cattle and buffalo. Mass inoculation of cattle and buffalo is being conducted on priority in India to prevent the spread of the disease from animals to human beings.
Guinea Pig Model Holds Promising Potentials to Develop Well-tolerated Brucellosis Vaccines
Apart from developing vaccines for animals, companies in the brucellosis vaccine market are diversifying their research capabilities to innovate in vaccines for humans.
In order to develop new vaccine candidates, there is a need to comply with the set industry standards before selecting the viral vectors and the method for preparing & using the vaccine. Companies are increasing their R&D capabilities using the study of protection of the vaccine with the help of guinea pigs, including various options for administering, dose, and frequency. They are innovating in brucellosis vaccines that can be well-tolerated in humans by upgrading the production technology and testing in healthcare practice.
Analysts’ Viewpoint
Stakeholders in the brucellosis vaccine market are reviewing financial assistance programs associated with COVID-19 appropriations for eligibility. Restricted budgets for brucellosis control in Colombia is affecting the overall animal welfare in the region. Hence, stakeholders in Colombia should increase efforts for important financial investments based on sustained cooperation between governmental institutions, industry, and farmers for developing affordable and effective strategies to control the disease. On-farm detection involves the use of a screening test, followed by a confirmatory test. Testing is mandatory for international trade, animal movements in Colombia, and for clinically suspected animals. This involves the Rose Bengal Plate Test (RBPT) or Indirect ELISA as a screening test.
Brucellosis Vaccine Market: Overview
Brucellosis Vaccine Market: Key Drivers
Brucellosis Vaccine Market: Segmentation
Brucellosis Vaccine Market: Regional Overview
Major Players
Brucellosis Vaccine Market Snapshot
Attribute |
Detail |
Market Size Value in 2020 |
US$ 253.1 Mn |
Market Forecast Value in 2031 |
US$ 387.4 Mn |
Growth Rate (CAGR) |
4% |
Forecast Period |
2021–2031 |
Quantitative Units |
US$ Mn for Value |
Market Analysis |
It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
Competition Landscape |
|
Format |
Electronic (PDF) + Excel |
Market Segmentation |
|
Regions Covered |
|
Countries Covered |
|
Companies Profiled |
|
Customization Scope |
Available upon request |
Pricing |
Available upon request |
Brucellosis Vaccine Market – Segmentation
TMR’s study on the global brucellosis vaccine market includes information divided into five segments: type, vaccine type, application, distribution channel, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global brucellosis vaccine market are discussed in detail.
Type |
|
Vaccine Type |
|
Application |
|
Distribution Channel |
|
Region |
|
Brucellosis vaccine market to reach valuation of US$ 387.4 Mn by 2031
Brucellosis vaccine market is projected to grow at a CAGR of 4% during 2021-2031
Brucellosis vaccine market is driven by increase in the number of animals suffering from brucellosis
The RB51 vaccine segment dominated the global brucellosis vaccine market in 2020, and the trend is expected to continue during the forecast period.
Key players operating in the global brucellosis vaccine market include Merck Animal Health, Ceva Sante Animale, CZ Vaccines, Colorado Serum Company, Indian Immunologicals Ltd.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Brucellosis Vaccine Market Forecast
4.4. Global Brucellosis Vaccine Market Outlook
5. Market Outlook
5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.2. Disease Prevalence globally with key countries
5.3. Regulatory Scenario
5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Brucellosis Vaccine Market Analysis and Forecast, by Type
6.1. Introduction
6.2. Global Brucellosis Vaccine Market Value Share Analysis, by Type
6.3. Global Brucellosis Vaccine Market Forecast, by Type
6.3.1. RB51 Vaccine
6.3.2. S19 Vaccine
6.3.3. Others
6.4. Global Brucellosis Vaccine Market Analysis, by Type
6.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Type
7. Global Brucellosis Vaccine Market Analysis and Forecast, by Vaccine Type
7.1. Introduction
7.2. Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type
7.3. Global Brucellosis Vaccine Market Forecast, by Vaccine Type
7.3.1. DNA Vaccine
7.3.2. Subunit Vaccine
7.3.3. Vector Vaccine
7.4. Recombinant Vaccine
7.5. Global Brucellosis Vaccine Market Analysis, by Vaccine Type
7.6. Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type
8. Global Brucellosis Vaccine Market Analysis and Forecast, by Application
8.1. Introduction
8.2. Global Brucellosis Vaccine Market Value Share Analysis, by Application
8.3. Global Brucellosis Vaccine Market Forecast, by Application
8.3.1. Cattle
8.3.2. Sheep & Goat
8.3.3. Others
8.4. Global Brucellosis Vaccine Market Analysis, by Application
8.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Application
9. Global Brucellosis Vaccine Market Analysis and Forecast, by Distribution Channel
9.1. Introduction
9.2. Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel
9.3. Global Brucellosis Vaccine Market Forecast, by Distribution Channel
9.3.1. Veterinary Hospitals & Clinics
9.3.2. Retail Channels
9.3.3. Others
9.4. Global Brucellosis Vaccine Market Analysis, by Distribution Channel
9.5. Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel
10. Global Brucellosis Vaccine Market Analysis, by Region
10.1. Global Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Region
10.2. Global Brucellosis Vaccine Market Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
11. North America Brucellosis Vaccine Market Analysis
11.1. North America Brucellosis Vaccine Market Overview
11.2. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country
11.3. North America Brucellosis Vaccine Market Forecast, by Country
11.3.1. U.S.
11.3.2. Canada
11.4. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type
11.5. North America Brucellosis Vaccine Market Forecast, by Type
11.5.1. RB51 Vaccine
11.5.2. S19 Vaccine
11.5.3. Others
11.6. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type
11.7. North America Brucellosis Vaccine Market Forecast, by Vaccine Type
11.7.1. DNA Vaccine
11.7.2. Subunit Vaccine
11.7.3. Vector Vaccine
11.7.4. Recombinant Vaccine
11.8. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application
11.9. North America Brucellosis Vaccine Market Forecast, by Application
11.9.1. Cattle
11.9.2. Sheep & Goat
11.9.3. Others
11.10. North America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel
11.11. North America Brucellosis Vaccine Market Forecast, by Distribution Channel
11.11.1. Veterinary Hospitals & Clinics
11.11.2. Retail Channels
11.11.3. Others
12. Europe Brucellosis Vaccine Market Analysis
12.1. Europe Brucellosis Vaccine Market Overview
12.2. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Europe Brucellosis Vaccine Market Forecast, by Country/Sub-region
12.3.1. Germany
12.3.2. U.K.
12.3.3. France
12.3.4. Spain
12.3.5. Italy
12.3.6. Rest of Europe
12.4. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type
12.5. Europe Brucellosis Vaccine Market Forecast, by Type
12.5.1. RB51 Vaccine
12.5.2. S19 Vaccine
12.5.3. Others
12.6. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type
12.7. Europe Brucellosis Vaccine Market Forecast, by Vaccine Type
12.7.1. DNA Vaccine
12.7.2. Subunit Vaccine
12.7.3. Vector Vaccine
12.7.4. Recombinant Vaccine
12.8. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application
12.9. Europe Brucellosis Vaccine Market Forecast, by Application
12.9.1. Cattle
12.9.2. Sheep & Goat
12.9.3. Others
12.10. Europe Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel
12.11. Europe Brucellosis Vaccine Market Forecast, by Distribution Channel
12.11.1. Veterinary Hospitals & Clinics
12.11.2. Retail Channels
12.11.3. Others
13. Asia Pacific Brucellosis Vaccine Market Analysis
13.1. Asia Pacific Brucellosis Vaccine Market Overview
13.2. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Asia Pacific Brucellosis Vaccine Market Forecast, by Country/Sub-region
13.3.1. China
13.3.2. Japan
13.3.3. India
13.3.4. Australia & New Zealand
13.3.5. Rest of Asia Pacific
13.4. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type
13.5. Asia Pacific Brucellosis Vaccine Market Forecast, by Type
13.5.1. RB51 Vaccine
13.5.2. S19 Vaccine
13.5.3. Others
13.6. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type
13.7. Asia Pacific Brucellosis Vaccine Market Forecast, by Vaccine Type
13.7.1. DNA Vaccine
13.7.2. Subunit Vaccine
13.7.3. Vector Vaccine
13.7.4. Recombinant Vaccine
13.8. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application
13.9. Asia Pacific Brucellosis Vaccine Market Forecast, by Application
13.9.1. Cattle
13.9.2. Sheep & Goat
13.9.3. Others
13.10. Asia Pacific Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel
13.11. Asia Pacific Brucellosis Vaccine Market Forecast, by Distribution Channel
13.11.1. Veterinary Hospitals & Clinics
13.11.2. Retail Channels
13.11.3. Others
14. Latin America Brucellosis Vaccine Market Analysis
14.1. Latin America Brucellosis Vaccine Market Overview
14.2. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Latin America Brucellosis Vaccine Market Forecast, by Country/Sub-region
14.3.1. Brazil
14.3.2. Mexico
14.3.3. Rest of Latin America
14.4. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type
14.5. Latin America Brucellosis Vaccine Market Forecast, by Type
14.5.1. RB51 Vaccine
14.5.2. S19 Vaccine
14.5.3. Others
14.6. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type
14.7. Latin America Brucellosis Vaccine Market Forecast, by Vaccine Type
14.7.1. DNA Vaccine
14.7.2. Subunit Vaccine
14.7.3. Vector Vaccine
14.7.4. Recombinant Vaccine
14.8. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application
14.9. Latin America Brucellosis Vaccine Market Forecast, by Application
14.9.1. Cattle
14.9.2. Sheep & Goat
14.9.3. Others
14.10. Latin America Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel
14.11. Latin America Brucellosis Vaccine Market Forecast, by Distribution Channel
14.11.1. Veterinary Hospitals & Clinics
14.11.2. Retail Channels
14.11.3. Others
15. Middle East & Africa Brucellosis Vaccine Market Analysis
15.1. Middle East & Africa Brucellosis Vaccine Market Overview
15.2. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Country/Sub-region
15.3. Middle East & Africa Brucellosis Vaccine Market Forecast, by Country/Sub-region
15.3.1. GCC Countries
15.3.2. South Africa
15.3.3. Rest of Middle East & Africa
15.4. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Type
15.5. Middle East & Africa Brucellosis Vaccine Market Forecast, by Type
15.5.1. RB51 Vaccine
15.5.2. S19 Vaccine
15.5.3. Others
15.6. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Vaccine Type
15.7. Middle East & Africa Brucellosis Vaccine Market Forecast, by Vaccine Type
15.7.1. DNA Vaccine
15.7.2. Subunit Vaccine
15.7.3. Vector Vaccine
15.7.4. Recombinant Vaccine
15.8. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Application
15.9. Middle East & Africa Brucellosis Vaccine Market Forecast, by Application
15.9.1. Cattle
15.9.2. Sheep & Goat
15.9.3. Others
15.10. Middle East & Africa Brucellosis Vaccine Market Value Share and Attractiveness Analysis, by Distribution Channel
15.11. Middle East & Africa Brucellosis Vaccine Market Forecast, by Distribution Channel
15.11.1. Veterinary Hospitals & Clinics
15.11.2. Retail Channels
15.11.3. Others
16. Competition Landscape
16.1. Company Profiles
16.1.1. Merck Animal Health
16.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.1.2. Product Portfolio
16.1.1.3. Financial Overview
16.1.1.4. SWOT Analysis
16.1.1.5. Strategic Overview
16.1.2. Ceva Sante Animale
16.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.2.2. Product Portfolio
16.1.2.3. SWOT Analysis
16.1.2.4. Strategic Overview
16.1.3. CZ Vaccines
16.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.3.2. Product Portfolio
16.1.3.3. SWOT Analysis
16.1.3.4. Strategic Overview
16.1.4. Colorado Serum Company
16.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.4.2. Product Portfolio
16.1.4.3. SWOT Analysis
16.1.4.4. Strategic Overview
16.1.5. Indian Immunologicals Ltd.
16.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.5.2. Product Portfolio
16.1.5.3. SWOT Analysis
16.1.5.4. Strategic Overview
16.1.6. Hester Biosciences Limited
16.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.6.2. Product Portfolio
16.1.6.3. Financial Overview
16.1.6.4. SWOT Analysis
16.1.6.5. Strategic Overview
16.1.7. Veterinary Technologies Corporation.
16.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.7.2. Product Portfolio
16.1.7.3. SWOT Analysis
16.1.7.4. Strategic Overview
16.1.8. Fivet Animal Health
16.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.8.2. Product Portfolio
16.1.8.3. SWOT Analysis
16.1.8.4. Strategic Overview
16.1.9. Jordan Bio-industries Center
16.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.9.2. Product Portfolio
16.1.9.3. SWOT Analysis
16.1.9.4. Strategic Overview
16.1.10. Laboratories Tornel
16.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.10.2. Product Portfolio
16.1.10.3. SWOT Analysis
16.1.10.4. Strategic Overview
List of Tables
Table 01: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2018–2030
Table 02: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 03: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 08: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 09: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 10: North America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 13: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 14: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 15: Europe Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 19: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 20: Asia Pacific Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 23: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 24: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 25: Latin America Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Type, 2017–2031
Table 28: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 29: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Middle East & Africa Brucellosis Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Brucellosis Vaccine Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Brucellosis Vaccine Market Value Share, by Type, 2020
Figure 03: Global Brucellosis Vaccine Market Value Share, by Vaccine Type, 2020
Figure 04: Global Brucellosis Vaccine Market Value Share, by Region, 2020
Figure 05: Global Brucellosis Vaccine Market Value Share, by Application, 2020
Figure 06: Global Brucellosis Vaccine Market Value Share, by Distribution Channel, 2020
Figure 07: Global Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 08: Global Brucellosis Vaccine Market Revenue (US$ Mn), by RB51 Vaccine, 2017–2031
Figure 09: Global Brucellosis Vaccine Market Revenue (US$ Mn), by S19 Vaccine, 2017–2031
Figure 10: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031
Figure 11: Global Brucellosis Vaccine Market Attractiveness Analysis, by Type, 2021–2031
Figure 12: Global Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 13: Global Brucellosis Vaccine Market Revenue (US$ Mn), by DNA Vaccine, 2017–2031
Figure 14: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Subunit Vaccine, 2017–2031
Figure 15: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Vector Vaccine, 2017–2031
Figure 16: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Recombinant Vaccine, 2017–2031
Figure 17: Global Brucellosis Vaccine Market Attractiveness Analysis, by Vaccine Type, 2021–2031
Figure 18: Global Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 19: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Cattle, 2017–2031
Figure 20: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Sheep & Goat, 2017–2031
Figure 21: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031
Figure 22: Global Brucellosis Vaccine Market Attractiveness Analysis, by Application, 2021–2031
Figure 23: Global Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 24: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Veterinary Hospitals & Clinics, 2017–2031
Figure 25: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Retail Channels, 2017–2031
Figure 26: Global Brucellosis Vaccine Market Revenue (US$ Mn), by Others, 2017–2031
Figure 27: Global Brucellosis Vaccine Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 28: Global Brucellosis Vaccine Market Value Share Analysis, by Region, 2020 and 2031
Figure 29: Global Brucellosis Vaccine Market Analysis, by Region, 2021-2031
Figure 30: North America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 31: North America Brucellosis Vaccine Market Value Share (%), by Country, 2020 and 2031
Figure 32: North America Brucellosis Vaccine Market Attractiveness, by Country, 2021–2031
Figure 33: North America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 34: North America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031
Figure 35: North America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 36: North America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 37: North America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 38: North America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031
Figure 39: North America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 40: North America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 41: Europe Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 42: Europe Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 43: Europe Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 44: Europe Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 45: Europe Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031
Figure 46: Europe Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 47: Europe Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 48: Europe Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 49: Europe Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031
Figure 50: Europe Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 51: Europe Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 52: Asia Pacific Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 53: Asia Pacific Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 54: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 55: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 56: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031
Figure 57: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 58: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 59: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 60: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031
Figure 61: Asia Pacific Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 62: Asia Pacific Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 63: Latin America Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 64: Latin America Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 65: Latin America Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 66: Latin America Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 67: Latin America Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031
Figure 68: Latin America Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 69: Latin America Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 70: Latin America Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 71: Latin America Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031
Figure 72: Latin America Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 73: Latin America Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 74: Middle East & Africa Brucellosis Vaccine Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 75: Middle East & Africa Brucellosis Vaccine Market Value Share (%), by Country/Sub-region, 2020 and 2031
Figure 76: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Country/Sub-region, 2021–2031
Figure 77: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Type, 2020 and 2031
Figure 78: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Type, 2021–2031
Figure 79: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Vaccine Type, 2020 and 2031
Figure 80: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 81: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Application, 2020 and 2031
Figure 82: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Application, 2021–2031
Figure 83: Middle East & Africa Brucellosis Vaccine Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 84: Middle East & Africa Brucellosis Vaccine Market Attractiveness, by Distribution Channel, 2021–2031